CL3‐024.

Methods	Six‐week double‐blind, randomised, multicentre study
Participants	In‐ and outpatients fulfilling DSM‐IV criteria for single or recurrent episode of Major Depressive Disorder (MDD), with or without melancholic features, without atypical features, without psychotic features and a score of at least 22 on Hamilton Rating Scale for Depression (HDRS). Age range: 18‐59 years Exclusion criteria: not specified
Interventions	Fluoxetine: 148 participants Agomelatine 25mg: 150 participants Agomelatine 50mg: 151 participants Fluoxetine dose: 20 mg/day Agomelatine dose range: 25‐50 mg/day
Outcomes	Primary outcome: HDRS score
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no other information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Double blind, no other information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no other information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information
Selective reporting (reporting bias)	Unclear risk	Insufficient information
Other bias	High risk	Funding: by industry